Table 5.

Clinical care of participants with follow-up questionnaire data who were newly diagnosed with COPD by case finding

		Listed on COPD register
		Yes (n=78)		No (n=297)
		N*	(%)	N*	(%)
Informed about COPD diagnosis		69	88.5	52	17.5
Annual review undertaken		65	83.3	103	34.7
Spirometry undertaken		68	87.2	111	37.4
Inhaler technique assessed		37	47.4	72	24.2
Antibiotics prescribed		14	17.9	18	6.1
Steroids prescribed		13	16.7	14	4.7
Influenza vaccine offered		77	98.7	242	81.5
Influenza vaccine received		67	85.9	207	69.7
Pneumococcal vaccine offered		44	56.4	128	43.1
Pneumococcal vaccine received		43	55.1	121	40.7
Pulmonary rehabilitation offered		4	5.1	5	1.7
Attended pulmonary rehabilitation		3	3.8	6	2
Smoking cessation advice given		44	56.4	103	34.7
Smoking cessation support offered†		34	43.6	60	20.2
Inhalers prescribed	SABA	45	57.7	87	29.3
	SAMA	21	26.9	18	6.1
	ICS	5	6.4	23	7.7
	LABA	0	0	5	1.7
	LAMA	7	9	1	0.3
	ICS/LABA	17	21.8	40	13.5
	LABA/LAMA	2	2.6	2	0.7
	Any of the above	58	74.4	104	35
Care plan provided		62	79.5	39	13.1
Clinical care score	<5	9	11.5	214	72.1
	5–9	56	71.8	76	25.6
	≥10	13	16.7	7	2.4
Median (IQR)	8	(6–9)	3	(2–5)

*Number of participants self-reporting having received the clinical intervention.

†19/25 (76%) smokers listed on the COPD Quality and Outcomes Framework (QOF) register received smoking cessation support and 34/54 (63%) smokers not listedon the COPD QOF register had received this.

COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; IQR, Interquartile range; LABA, long acting beta 2 agonist; LAMA, long acting muscarinic antagonist; SABA, short acting beta 2 antagonist; SAMA, short acting muscarinic antagonist.